SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Febantel / Pyrantel Pamoate / Praziquantel
Formulation

Version 2.1  Revision Date: 27.08.2021  SDS Number: 3784229-00010  Date of last issue: 09.04.2021
Date of first issue: 19.11.2018

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
Trade name : Febantel / Pyrantel Pamoate / Praziquantel Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
Use of the Substance/Mixture : Veterinary product

1.3 Details of the supplier of the safety data sheet
Company : MSD
Kilsheelan
Clonmel Tipperary, IE
Telephone : 353-51-601000
E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
Classification (REGULATION (EC) No 1272/2008)
Long-term (chronic) aquatic hazard, Category 1
H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements
Labelling (REGULATION (EC) No 1272/2008)
Hazard pictograms : 
Signal word : Warning
Hazard statements : H410 Very toxic to aquatic life with long lasting effects.
Precautionary statements : Prevention:
P273 Avoid release to the environment.
Response:
P391 Collect spillage.
Additional Labelling
The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: 21.82 %

2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Febantel</td>
<td>58306-30-2</td>
<td>261-205-0</td>
<td></td>
<td></td>
<td>Acute Tox. 4; H302 Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 1 M-Factor (Chronic aquatic toxicity): 10 Acute toxicity estimate Acute oral toxicity: 1.250 mg/kg</td>
<td>&gt;= 20 - &lt; 25</td>
</tr>
<tr>
<td>4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1)</td>
<td>22204-24-6</td>
<td>244-837-1</td>
<td></td>
<td></td>
<td></td>
<td>&gt;= 20 - &lt; 30</td>
</tr>
<tr>
<td>praziquantel</td>
<td>55268-74-1</td>
<td>259-559-6</td>
<td></td>
<td></td>
<td>Aquatic Chronic 3; H412</td>
<td>&gt;= 2,5 - &lt; 10</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Febantel / Pyrantel Pamoate / Praziquantel Formulation

Version 2.1 Revision Date: 27.08.2021 SDS Number: 3784229-00010 Date of last issue: 09.04.2021
Date of first issue: 19.11.2018

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.

In case of skin contact: Wash with water and soap. Get medical attention if symptoms occur.

In case of eye contact: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks: Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.
Febantel / Pyrantel Pamoate / Praziquantel Formulation

5.2 Special hazards arising from the substance or mixture

Specific hazards during firefighting:
Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
- Carbon oxides
- Nitrogen oxides (NOx)
- Sulphur oxides

5.3 Advice for firefighters

Special protective equipment for firefighters:
In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions:
Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions:
Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up:
Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Febantel / Pyrantel Pamoate / Praziquantel
Formulation

Version 2.1  Revision Date: 27.08.2021  SDS Number: 3784229-00010  Date of last issue: 09.04.2021

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling:
- Do not breathe dust.
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Minimize dust generation and accumulation.
- Keep container closed when not in use.
- Keep away from heat and sources of ignition.
- Take precautionary measures against static discharges.
- Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers: Keep in properly labelled containers. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types: Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s): No data available
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Febantel / Pyrantel Pamoate / Praziquantel
Formulation

Version 2.1  Revision Date: 27.08.2021  SDS Number: 3784229-00010  Date of last issue: 09.04.2021
Date of first issue: 19.11.2018

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>4,4’-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thieryl)vinyl]pyrimidine (1:1)</td>
<td>22204-24-6</td>
<td>TWA</td>
<td>250 µg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>praziquantel</td>
<td>55268-74-1</td>
<td>TWA</td>
<td>0.5 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>praziquantel</td>
<td>Fresh water</td>
<td>0.3 mg/l</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material: Chemical-resistant gloves

Remarks: Consider double gloving.

Skin and body protection: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to NS EN 143.

Filter type: Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state: powder

Colour: yellow

Odour: No data available

Odour Threshold: No data available

Melting point/freezing point: No data available

Initial boiling point and boiling range: No data available

Flammability (solid, gas): May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids): Not applicable

Upper explosion limit / Upper flammability limit: No data available

Lower explosion limit / Lower flammability limit: No data available

Flash point: Not applicable

Auto-ignition temperature: No data available

 Decomposition temperature: No data available

pH: No data available

Viscosity

Viscosity, kinematic: Not applicable

Solubility(ies)

Water solubility: No data available

Partition coefficient: n-octanol/water: Not applicable

Vapour pressure: Not applicable

Relative density: No data available

Density: No data available

Relative vapour density: Not applicable
Particle characteristics
  Particle size : No data available

9.2 Other information
  Explosives : Not explosive
  Oxidizing properties : The substance or mixture is not classified as oxidizing.
  Evaporation rate : Not applicable
  Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
  Not classified as a reactivity hazard.

10.2 Chemical stability
  Stable under normal conditions.

10.3 Possibility of hazardous reactions
  Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

10.4 Conditions to avoid
  Conditions to avoid : Heat, flames and sparks. Avoid dust formation.

10.5 Incompatible materials
  Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products
  No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008
  Information on likely routes of exposure : Inhalation
  Skin contact
  Ingestion
  Eye contact

  Acute toxicity
  Not classified based on available information.

  Product:
  Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg
### Components:

#### Febantel:

- **Acute oral toxicity**: LD₅₀ (Rabbit): 1.250 mg/kg  
  Acute toxicity estimate: 1.250 mg/kg  
  Method: Calculation method

- **Acute dermal toxicity**: LD₅₀ (Rabbit): > 2.000 mg/kg

#### 4,4’-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

- **Acute oral toxicity**:  
  LD₅₀ (Rat): > 24.000 mg/kg  
  LD₅₀ (Mouse): > 24.000 mg/kg  
  LD₅₀ (Dog): 2.000 mg/kg

- **praziquantel**:

  - **Acute oral toxicity**:  
    LD₅₀ (Rat): 2.480 mg/kg  
    LD₅₀ (Mouse): 2.454 mg/kg  
    LD₅₀ (Dog): > 200 mg/kg  
    LD₅₀ (Rabbit): 1.050 mg/kg

#### Skin corrosion/irritation

Not classified based on available information.

### Components:

#### Febantel:

- **Species**: Rabbit  
  **Result**: No skin irritation

#### praziquantel:

- **Species**: Rabbit  
  **Method**: Draize Test  
  **Remarks**: slight irritation

### Serious eye damage/eye irritation

Not classified based on available information.
Febantel / Pyrantel Pamoate / Praziquantel
Formulation

Species: Rabbit
Result: No eye irritation

**praziquantel:**
Species: Rabbit
Method: Draize Test
Result: Mild eye irritation

**Respiratory or skin sensitisation**

**Skin sensitisation**
Not classified based on available information.

**Respiratory sensitisation**
Not classified based on available information.

**Components:**

**praziquantel:**
Test Type: Maximisation Test
Exposure routes: Dermal
Species: Guinea pig
Result: Not a skin sensitizer.

**Germ cell mutagenicity**
Not classified based on available information.

**Components:**

**Febantel:**
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Result: negative

Genotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

**4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):**
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

**praziquantel:**
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Febantel / Pyrantel Pamoate / Praziquantel
Formulation

Result: negative
Test Type: Chromosomal aberration
Test system: Chinese hamster cells
Result: negative

Genotoxicity in vivo:
Test Type: Micronucleus test
Species: Rat
Result: negative

Carcinogenicity
Not classified based on available information.

Components:

Febantel:
Species: Mouse
Application Route: Ingestion
Exposure time: 21 Months
Result: negative

praziquantel:
Species: Hamster
Application Route: Oral
Exposure time: 80 weeks
NOAEL: 100 mg/kg body weight
Result: negative
Remarks: No significant adverse effects were reported

Species: Rat
Application Route: Oral
Exposure time: 104 weeks
NOAEL: 250 mg/kg body weight
Result: negative
Remarks: No significant adverse effects were reported

Reproductive toxicity
Not classified based on available information.

Components:

Febantel:
Effects on fertility:
Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 416
Result: negative

Effects on foetal development:
Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Febantel / Pyrantel Pamoate / Praziquantel Formulation

<table>
<thead>
<tr>
<th>Method: OECD Test Guideline 416</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result: negative</td>
</tr>
</tbody>
</table>

4,4’-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

<table>
<thead>
<tr>
<th>Effects on foetal development</th>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
<td></td>
</tr>
<tr>
<td>Application Route: Oral</td>
<td></td>
</tr>
<tr>
<td>Developmental Toxicity: NOAEL: 3,000 mg/kg body weight</td>
<td></td>
</tr>
<tr>
<td>Result: No effects on fertility and early embryonic development were detected.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rabbit</td>
</tr>
<tr>
<td>Application Route: Oral</td>
</tr>
<tr>
<td>Developmental Toxicity: NOAEL: 1,000 mg/kg body weight</td>
</tr>
<tr>
<td>Result: No effects on fertility and early embryonic development were detected.</td>
</tr>
</tbody>
</table>

Praziquantel:

<table>
<thead>
<tr>
<th>Effects on fertility</th>
<th>Test Type: Fertility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
<td></td>
</tr>
<tr>
<td>Remarks: No significant adverse effects were reported</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type: Fertility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Mouse</td>
</tr>
<tr>
<td>Remarks: No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Effects on foetal development</th>
<th>Test Type: Development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
<td></td>
</tr>
<tr>
<td>Remarks: No significant adverse effects were reported</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type: Development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Mouse</td>
</tr>
<tr>
<td>Remarks: No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.

Repeated dose toxicity

Components:

4,4’-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

| Species: Dog | |
| NOAEL: 10 mg/kg | |
| LOAEL: 30 mg/kg | |
## Febantel / Pyrantel Pamoate / Praziquantel Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>27.08.2021</td>
<td>3784229-00010</td>
<td>09.04.2021</td>
<td>19.11.2018</td>
</tr>
</tbody>
</table>

**Application Route:** Ingestion  
**Exposure time:** 3 d  
**Remarks:** No significant adverse effects were reported

**Species:** Dog  
**NOAEL:** 600 mg/kg  
**Application Route:** Oral  
**Exposure time:** 19 d  
**Remarks:** No significant adverse effects were reported

**Species:** Dog  
**NOAEL:** 600 mg/kg  
**Application Route:** Oral  
**Exposure time:** 30 d  
**Remarks:** No significant adverse effects were reported

**Species:** Dog  
**NOAEL:** 600 mg/kg  
**Application Route:** Oral  
**Exposure time:** 90 d  
**Remarks:** No significant adverse effects were reported

**praziquantel:**

**Species:** Rat  
**NOAEL:** 1,000 mg/kg  
**Application Route:** Oral  
**Remarks:** No significant adverse effects were reported

**Species:** Dog  
**NOAEL:** 60 mg/kg  
**LOAEL:** 180 mg/kg  
**Application Route:** Oral  
**Target Organs:** Gastrointestinal tract  
**Remarks:** No significant adverse effects were reported

**Aspiration toxicity**  
Not classified based on available information.

### 11.2 Information on other hazards

**Endocrine disrupting properties**

**Product:**

**Assessment:** The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
Experience with human exposure

Components:

4,4’-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):
Ingestion: Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhoea, Headache, Dizziness, Fever

praziquantel:
Inhalation: Symptoms: Headache, Tiredness, Dizziness, Gastrointestinal discomfort, decrease body temperature, Allergic reactions

SECTION 12: Ecological information

12.1 Toxicity

Components:

Febantel:
Toxicity to fish: LC50 (Danio rerio (zebra fish)): > 100 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 0.2 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants: ErC50 (Desmodesmus subspicatus (green algae)): > 0.43 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity): 1

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC: > 0.001 - 0.01 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211
Remarks: Based on data from similar materials

M-Factor (Chronic aquatic toxicity): 10

4,4’-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Ecotoxicology Assessment
Acute aquatic toxicity: Toxic effects cannot be excluded
Chronic aquatic toxicity: Toxic effects cannot be excluded

praziquantel:
Febantel / Pyrantel Pamoate / Praziquantel
Formulation

Toxicity to fish:
- LC50 (Carassius auratus (goldfish)): 29.2 mg/l
  Exposure time: 96 hrs
  Method: OECD Test Guideline 203
- LC50 (Danio rerio (zebra fish)): 31.6 mg/l
  Exposure time: 96 hrs
  Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates:
- EC50 (Daphnia magna (Water flea)): 35 mg/l
  Exposure time: 48 h
  Method: OECD Test Guideline 202

Toxicity to microorganisms:
- EC50 (activated sludge): > 1.000 mg/l
  Exposure time: 3 h
  Test Type: Respiration inhibition of activated sludge
  Method: OECD Test Guideline 209

12.2 Persistence and degradability
No data available

12.3 Bioaccumulative potential
Components:
Febantel:
- Partition coefficient: n-octanol/water: log Pow: 1.95
- Remarks: Calculation

Praziquantel:
- Partition coefficient: n-octanol/water: log Pow: 2.012
  pH: 7

12.4 Mobility in soil
No data available

12.5 Results of PBT and vPvB assessment
Product:
Assessment: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties
Product:
Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Febantel / Pyrantel Pamoate / Praziquantel
Formulation

12.7 Other adverse effects
No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods
Product: Dispose of in accordance with local regulations.
According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.
Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number
ADN: UN 3077
ADR: UN 3077
RID: UN 3077
IMDG: UN 3077
IATA: UN 3077

14.2 UN proper shipping name
ADN: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Febantel)
ADR: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Febantel)
RID: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Febantel)
IMDG: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Febantel)
IATA: Environmentally hazardous substance, solid, n.o.s. (Febantel)

14.3 Transport hazard class(es)
ADN: 9
ADR: 9
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Febantel / Pyrantel Pamoate / Praziquantel
Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>27.08.2021</td>
<td>3784229-00010</td>
<td>09.04.2021</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Date of first issue: 19.11.2018</td>
</tr>
</tbody>
</table>

RID : 9
IMDG : 9
IATA : 9

14.4 Packing group

ADN
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

ADR
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

IMDG
Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)
Packing instruction (cargo aircraft) : 956
Packing instruction (LQ) : Y956
Packing group : III
Labels : Miscellaneous

IATA (Passenger)
Packing instruction (passenger aircraft) : 956
Packing instruction (LQ) : Y956
Packing group : III
Labels : Miscellaneous

14.5 Environmental hazards

ADN
Environmentally hazardous : yes

ADR
Environmentally hazardous : yes

RID
Environmentally hazardous : yes

IMDG
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Febantel / Pyrantel Pamoate / Praziquantel
Formulation

Version 2.1
Revision Date: 27.08.2021
SDS Number: 3784229-00010
Date of last issue: 09.04.2021
Date of first issue: 19.11.2018

Marine pollutant : yes

IATA (Passenger)
Environmentally hazardous : yes

IATA (Cargo)
Environmentally hazardous : yes

14.6 Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments
Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII): Not applicable
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59): Not applicable
REACH - List of substances subject to authorisation (Annex XIV): Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer: Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast): Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals: Not applicable

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Febantel / Pyrantel Pamoate / Praziquantel
Formulation

Version 2.1 Revision Date: 27.08.2021 SDS Number: 3784229-00010 Date of last issue: 09.04.2021 Date of first issue: 19.11.2018

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements
H302: Harmful if swallowed.
H400: Very toxic to aquatic life.
H410: Very toxic to aquatic life with long lasting effects.
H412: Harmful to aquatic life with long lasting effects.

Full text of other abbreviations
Acute Tox.: Acute toxicity
Aquatic Acute: Short-term (acute) aquatic hazard
Aquatic Chronic: Long-term (chronic) aquatic hazard

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information
Febantel / Pyrantel Pamoate / Praziquantel
Formulation

Classification of the mixture:
Aquatic Chronic 1

Classification procedure:
H410
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

NO / EN